BACKGROUND: We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination re...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!